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patient. Compared to symptomatic therapy, patient with AR treated with allergen
immunotherapy obtained approx. 0.75 month (3 years of vaccination followed by
5-year evaluation) and 3.45 month (4-year follow up including 3 years of vaccina-
tion) without AB. The QALY for costs has been calculated between 8516 € - 8883 €.
CONCLUSIONS: In the Slovak Republic, Staloral allergen immunotherapy of aller-
gic rhinitis is effective from the clinical as well as pharmacoeconomic point of
view.
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OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) poses a significant
burden on health care budgets. The impact of impaired and lost productivity is less
known. The aim of this study was to explore the economic burden of COPD in
patients of working age in The Netherlands across three areas: health care utiliza-
tion, impaired productivity and lost productivity resulting from early retirement
due to COPD. METHODS: Dutch direct medical costs were derived from a literature
review and applied to individual COPD patients. Costs of productivity impairment
due to COPD were estimated from the ‘COPD uncovered’ survey, adopted for The
Netherlands. Costs due to lost productivity due to early retirement were based on
a cohort of COPD patients of working age followed in a Markov model for 20 years
until (early) retirement or death. The costing year was 2011. RESULTS: The annual
health care costs for patients with COPD aged 45-64 years in The Netherlands were
estimated at around €70 million. The annual impaired productivity costs were €120
million. Lost productivity due to early retirement were estimated at around €510
million per year; the majority of €350 million for men and €160 million for women.
These lost productivity costs represented 21% of the productivity that may have
been generated by COPD patients if they had not retired early. CONCLUSIONS: The
‘COPD UNCOVERED’ model was used to estimate the economic burden of COPD in
The Netherlands. Costs due to impaired and lost productivity in COPD patients of
working age was considerable and several times higher than the medical cost of
COPD. Young working population provide a main target for interventions aimed to
improve COPD disease management.
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OBJECTIVES: According to the GOLD report (2011), COPD is associated with signif-
icant economic burden. For Ukraine as for developing country, the human capital
(employed economically active population) is the most important national asset
and COPD-related work-place loss may represent a serious threat for Ukrainian
economics. METHODS: Via the best fit (least square) linear regression forecast we
modeled the 2012-2020 dynamics of the key socioeconomic and COPD-related ep-
idemiological indicators for general Ukrainian population and employed econom-
ically active population. Modeling was based on the 2005-2011 reports of the Ukrai-
nian National Center of Statistics and data from WHO. Using forecasting results the
number of new COPD cases and COPD-related deaths 2012-2020 was calculated.
Also we calculated and compared 2012 and 2020 direct and indirect costs.
RESULTS: According to the forecasting results, number of total Ukrainian popula-
tion and employed economically active population could amount 45453100 and
20393267, respectively, in 2012 and 43484907 and 20845448, respectively, in 2020.
Number of COPD patients in 2012 and 2020 could be 1766748 and 1731332, respec-
tively, in general population and 792680 and 829952, respectively, in employed
economically active population. Number of 2012-2020 new COPD cases and COPD
related deaths could be 1230750 and 56207, respectively, in general population and
570737 and 25892, respectively, in employed economically active population. We
estimated that in 2012 direct COPD costs could be 87,17% greater than indirect
COPD costs and could amount to €326367598 vs. €193607579,9, respectively. In 2020
indirect COPD costs could 1,47% exceed the direct costs and could amount
€496997427,8 vs. 489796409, respectively. CONCLUSIONS: Results of modeling
show that socioeconomic burden of COPD will be significant for Ukraine during the
2012-2020 periods. COPD costs will rise with the significant growth of indirect costs,
which may be typically for Ukraine as for developing country.
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OBJECTIVES: Asthma, a major chronic respiratory disease, has become a cause of
global concern in terms of its increasing prevalence, morbidity and economic im-
pact.Our aim was to examine the availability, pricing and affordability of asthma
medicines in Tehran. METHODS: The study methodology was designed using the
recommendations developed by the World Health Organization and Health Action
International on measuring medicine prices, availability, affordability and price
components. Data was collected from 5 public sector facilities and 10 private sector
retail pharmacies in the pilot study in 22 regions of Tehran.Data on price of inno-
vator brands (IBs) and lowest priced generics (LPGs) found at each facility were
gathered and applied for data analtysis. RESULTS: Generic beclomethasone was
found in 3 public sectors and generic salbutamol was available in 4 public sec-
tors.The availability of IB beclomethasone was poor in all of the regions surveyed
.IB beclomethasone was available at 2 out of 5 and 5 out of 10 pharmacies surveyed
in public and private sectors, respectively. The availability of generic beclometha-
sone inhalers was 90%. IB salbutamol inhalers were available in all the surveyed
regions.At the time of the survey, the lowest paid unskilled government worker
earned 108 400 Iranian Rials (IRR) (US$ 11.78) per day. CONCLUSIONS: The poor
availability of inhalers at public facilities affects those patients who depend on
these facilities for treatment and medications. In the past decade, some barriers
were imposed by the Ministry of Health on registering certain pharmaceuticals . A
new approach has focused on reducing these barriers and there is a need for stron-
ger government action to introduce or improve national medicine policy as well as
effective pricing policies.
PRS18
SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS, UTILITY ESTIMATES,
RESOURCE UTILISATION, AND COSTS IN CHRONIC IDIOPATHIC URTICARIA
Woods MS1, Zimovetz E1, Beard S1, Balp MM2
1RTI Health Solutions, Manchester, UK, 2Novartis Pharma AG, Basel, Switzerland
OBJECTIVES: To systematically identify economic evaluations of treatments rec-
ommended for chronic idiopathic urticaria (CIU) and studies reporting health-state
utility weights and/or estimates of resource use and costs. METHODS: Systematic
searches of MEDLINE, MEDLINE-In-Process, EconLit, EMBASE, the Cochrane Li-
brary, and conference abstracts were conducted from 1 January 2000 to 20 Decem-
ber 2011. Inclusion criteria considered studies reporting utility weights, resource
use, costs, and/or economic evaluations of treatments in CIU patients older than 12
years. RESULTS: From 266 retrieved records, 3 studies were included: 1 economic
evaluation of levocetirizine and 2 cost studies. The economic evaluation was a
pooled analysis of two clinical trials comparing levocetirizine with placebo and
incorporating productivity losses defined as absenteeism and/or presenteeism.
One cost study reported total annual per-patient direct costs of $1,762; the other
study reported a cost range between $1,290 and $2,419, depending on disease se-
verity. Cost components included prescriptions, visits, hospitalisations, and labo-
ratory costs. Annual per-patient indirect costs, defined as disease-related loss of
earnings, were between $213 and $484, depending on severity. Although no utility
studies in CIU were found, one study demonstrated that CIU severely impairs
health-related quality of life at the same level as skin conditions, such as psoriasis
and atopic dermatitis, on certain dimensions. CONCLUSIONS: This review identi-
fied limited evidence on costs, only one economic evaluation, and no utility data for
CIU. Lacking comparative data, it is impossible to conclude what the most cost-
effective treatment in CIU might be. Due to discrepancies between the cost studies,
it is difficult to conclude which cost component contributed the most; however,
one study reported that productivity loss was a major component. This review
highlighted the substantial cost burden and a humanistic burden, comparable to
other skin disorders, of CIU. Further research in this area is needed.
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OBJECTIVES: According to the GOLD report (2011) COPD is associated with signifi-
cant economic burden. COPD exacerbations account for the greatest proportion of
the total COPD costs. Frequency and severity of COPD exacerbation could be re-
duced by the appropriate medication that could be reimbursed by Ukrainian
Government.METHODS:To determine the net benefit ratio we assessed total COPD
costs and the COPD exacerbation-related costs reduction as benefit (effectiveness)
for tiotropium (18 mcg daily) and salmeterol (50 mcg two times a day) compared to
usual COPD treatment practice of GPs. Direct costs included medication costs,
outpatient and inpatient costs. Indirect costs included productivity loss and tem-
porary disability related payments. Calculations were performed per 1000 em-
ployed economically active COPD patients. The data about the outpatient visits and
hospitalizations was received from results of Ukrainian retrospective study (for
usual practice regimen) and from the POET study results (for tiotropium and sal-
meterol). Prices for medical services were received from appropriate survey (2011)
and were counted with May 2011-May 2012 inflation index and salary growth rates.
The minimal market medication prices (on 15 June 2012) were included in calcula-
tions. Sensitivity analysis was conducted with medication price decrease.
RESULTS: Results show that total COPD costs per 1000 employed economically
active COPD patients in 2012 could amount €498052,34, €441697,07 and €508983,73
with usual COPD treatment practice of GPs, salmeterol and tiotropium, respec-
tively. Reduction of exacerbation-related COPD costs compared to usual practice
could amount €85698,78 for salmeterol and €114380,78 for tiotropium. Cost benefit
ratio for salmeterol could be 5,15 and for tiotropium could be 4,45. In case of 27%
price drop salmeterol could be more beneficial than tiotropium. CONCLUSIONS:
According to results of the cost-benefit analysis tiotropium is more beneficial for
COPD basis in employed economically active Ukrainian population than salmeterol
compared to usual practice. It could be reimbursed by Ukrainian government.
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OBJECTIVES: Treprostinil is available in two forms (inhaled vs. infused) for the
treatment of patients with pulmonary arterial hypertension (PAH) and New York
Heart Association (NYHA) Class II-IV symptoms. The preference from 384 members
of the general public for the inhaled form, and this population’s willingness-to-pay
(WTP) in additional monthly insurance premiums for the inclusion of this treat-
ment on a hypothetical insurance scheme have been previously reported. The
present cost-benefit analysis (CBA) explored whether it would be cost-beneficial to
include inhaled treprostinil to a list of medications reimbursed by private third-
party payers in Canada, for PAH NYHA Class III patients. METHODS: The CBA was
based on a hypothetical population of 100,000. Total yearly benefits were calculated
by targeting subjects 18 years of age or older and active in the workforce, applying
the percentage of subjects who prefer inhaled treprostinil to infused treprostinil
(85.8%) and their median monthly WTP ($CAD21.50) multiplied by 12. Potential
costs were evaluated by estimating the number of potential PAH patients in the
hypothetical cohort, 18 years of age or older and in NYHA Class III category, mul-
tiplied by the annual cost of using inhaled treprostinil ($117,893). The final cost-
benefit to third-party payers was appraised by subtracting the potential costs from
the potential benefits. RESULTS: Based on prevalence rates, the hypothetical start-
ing cohort would yield 2 patients, resulting in expected costs of $235,786 to third-
party payers. The estimated number of subjects willing to pay for the inclusion of
inhaled treprostinil on the formulary of reimbursed drugs was 37,540, generating
benefits of $9,685,320. Hence, the expected difference (benefits minus costs) was
$9,449,534. CONCLUSIONS: The inclusion of inhaled treprostinil to formularies of
reimbursed medications would be highly cost-beneficial to private third-party pay-
ers in the province of Ontario, Canada, for patients with PAH and NYHA Class III
symptoms.
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OBJECTIVES: Fixed combinations of inhaled corticosteroids and long-acting 2-
agonists are widely used in treatment of patients with chronic obstructive pulmo-
nary disease (COPD) to reduce exacerbations. Cost-effectiveness analyses compar-
ing the costs and effects of the fixed combinations budesonide/formoterol and
fluticasone/salmeterol in COPD are scarce. The objective of this study was to eval-
uate the cost-effectiveness of budesonide/formoterol relative to fluticasone/sal-
meterol based on up to eleven years of real-world effectiveness data (NCT01146392)
from a Swedish health care perspective. METHODS: Resource use and effective-
ness data were collected retrospectively from primary care medical records’ data,
patients 18 years, both sexes, with a diagnosis of COPD (J44) and merged with
Swedish hospital, drug, and cause of death register data from 1 January 1999 to 31
December 2009. Propensity score matching of treatment groups was done at the
index date (first prescription of fixed combination post COPD diagnosis). Exacerba-
tions were defined as hospitalisations and emergency room visits for COPD, pre-
scription of glucocorticosteroids and/or prescription of antibiotics for respiratory
tract infections. Annual exacerbation rates were calculated using Poisson regres-
sion. The effectiveness variable was the number of exacerbations avoided. Direct
costs were calculated by applying year 2010 Swedish unit costs to the annual re-
source use. Bootstrapping was used to quantify uncertainty around estimates.
RESULTS: Based on 2734 patients in each treatment group, the annual exacerba-
tion rate was 0.800 for patients treated with budesonide/formoterol and 1.090 for
patients treated with fluticasone/salmeterol (26.6% reduction, p0.0001). Treat-
ment with budesonide/formoterol was found to be cost-saving compared with
treatment with fluticasone/salmeterol (total average annual per patient cost of
SEK12 580 [€1318] and SEK15 979 [€1675], respectively). CONCLUSIONS: Budes-
onide/formoterol was the dominant strategy (more effective at lower cost) com-
pared to fluticasone/salmeterol for the treatment of patients with COPD based on
11 years of real-world effectiveness data.
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OBJECTIVES: To estimate the cost-effectiveness of Beclomethasone/Formoterol
(BF) versus Fluticasone/Salmeterol (FS) in the treatment of adult out-patients with
moderate to severe asthma from the perspective of the Society in Spain.
METHODS: A Markov model was developed with five asthma health states: suc-
cessful control, sub-optimal control, outpatient-managed exacerbation, inpatient-
managed exacerbation, and death. Weekly transition probabilities were derived
from the published 12-weeks ICAT SE study. Resources utilization were obtained
from a published Spanish study designed ad-hoc to ascertain health care resources
utilization, the so-called lost-workday-equivalents, and corresponding costs re-
lated with treatment of asthma in the year 2011. Time horizon was set at 12 weeks
in the basecase scenario. Effectiveness was expressed as quality-adjusted life years
(QALY) gain. The cost-effectiveness was expressed as an incremental cost effec-
tiveness ratio (ICER). Bootstrapping techniques (10,000 re-samples) were used to
obtain the probabilistic ICER, its 95% percentile confidence interval (CI) and the
cost-effectiveness acceptability curve. Univariate and probabilistic sensitivity
analysis (PSA) were also applied and included, among others, extension of the
horizon to one year and the perspective of the NHS only. RESULTS: Compared with
FS, BF was associated with a slightly increase in QALY gain; 0,7974 vs. 0,7945 while
differential costs were always lower favoring BF and yielding to a mean ICER dom-
inant (95% CI: dominant; €46,930) per QALY gained. In 96% of re-samples, the ICER
was below the threshold of €30,000 per QALY, considered as cost-effective in Spain.
Univariate and PSA were robust and confirmed results of the basecase scenario.
CONCLUSIONS: From the Spanish societal and NHS perspectives in year 2011,
Becomethasone/Formoterol produced similar QALY gain at a lower cost when com-
pared with Fluticasone/Salmeterol in a highly meaningful number of replications
and scenarios. Thus, Beclomethasone/Formoterol may be considered a cost-effec-
tive alternative in the treatment of moderate to severe asthma in Spain.
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OBJECTIVES: To conduct comparative pharmacoeconomic analysis of
roflumilastformoterol versus formoterol monotherapy in adult patients with se-
vere-to-very severe COPD. METHODS: Analysis of the published clinical trials was
conducted to evaluate comparative efficacy and safety of the studied therapy op-
tions. Expected difference in direct medical costs was calculated in Excel model
based on clinical trial data about decreased number of exacerbations on
roflumilastformoterol therapy. 1-year costs of treatment were calculated from
the Russian health care system point of view. Parameter uncertainty was explored
using one-way sensitivity analysis. RESULTS: Patients on combination therapy
have 20.7% less exacerbations that leads to decreased costs of treatment. The
annual treatment cost per 1 patient was 37.93 USD less for roflumilastformoterol
therapy than for formoterol. The one-way sensitivity analysis showed that the
results are sensitive to the variations of key model parameters: for example com-
bination therapy remained the cheaper alternative when the price for roflumilast
was no more than  5.0-5.2% from the basic level. CONCLUSIONS: The combina-
tion of roflumilast  formoterol on average was more effective and cost-saving
treatment option for patients with severe-to-very severe COPD, but the results are
sensitive to the variations of price of roflumilast, the length of stay costs and the
duration of hospital stay for COPD exacerbations.
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OBJECTIVES: Austria’s smoking-rate is among the world highest. Varenicline has
been shown to be an effective and well-tolerated intervention for smoking cessa-
tion. The objective of this study was to evaluate and compare the cost-effective-
ness of varenicline with bupropion and nicotine-replacement-therapy (NRT) for
smoking cessation in Austria. METHODS: A markov-model was used to demon-
strate the Benefits of Smoking Cessation on Outcomes (BENESCO model). The
model simulates the incidence of four smoking-related morbidities: lung-cancer,
chronic-obstructive-pulmonary-disease, coronary-heart-disease and stroke. The
model computes costs, quality-adjusted-life-years (QALYs) and life-years (LYs)
gained. Incremental cost-utility-ratios were calculated, adopting a lifetime per-
spective. Efficacy data were obtained from a pooled varenicline phase 3a studies
(22.5% for varenicline and 15.7% for bupropion) and from Silagy(2005) for NRT
(15.5%). QALYs, life-years and costs were discounted at 5% p.a. RESULTS: The anal-
yses imply that for Austria, smoking cessation using varenicline versus budropion
or NRT is associated with reduced smoking-related morbidity and mortality. The
number of morbidities and mortalities avoided over lifetime, per 1000 smokers
attempting to quit, amounts to 7.36 cases of morbidities and 4.14 deaths if vareni-
cline is used instead of bupropion and 7.40 morbidities and 4.14 mortalities when
varenicline is used in place of NRT. The number of QALYs gained over lifetime, per
1000 smokers, was 16.64 (15.32 LYs gained) in case of varenicline vs. bupropion and
16.74 QALYs gained (15.40 LYs gained) for varenicline vs. NRT. The incremental
cost-utility-ratio of varenicline vs. bupropion amounts to 5,367€ and for varenicline
vs. NRT it is 4,070€. Additional costs were paid out-of-pocket. Probabilistic-sensi-
tivity-analyses demonstrated the robustness of the model regarding assumptions
and input-parameters. CONCLUSIONS: This cost-effectiveness analysis demon-
strated that varenicline treatment is cost-effective in Austria. Our results suggest
that funding varenicline as a smoking cessation aid is justifiable from a health care
resource allocation perspective.
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